EVI2B inhibitors refer to a class of chemical compounds that are specifically designed to target and modulate the activity of the EVI2B protein. EVI2B, or Ecotropic Viral Integration Site 2B, is a transmembrane protein associated with various cellular processes, including signal transduction, membrane dynamics, and protein trafficking. While the primary function of EVI2B remains a subject of ongoing research, it is often implicated in regulating key cellular pathways, making it an attractive target for scientific investigation.
These inhibitors are meticulously designed to interfere with EVI2B's function by either directly binding to the protein or disrupting its associated signaling pathways. The mechanisms of action can vary widely among EVI2B inhibitors, but their overarching goal is to modulate the cellular responses and functions influenced by EVI2B. Researchers have developed a diverse range of small molecules that belong to the EVI2B inhibitor class, each with distinct chemical structures and modes of action. These inhibitors have become valuable tools in deciphering the precise roles of EVI2B in cellular processes and understanding its contributions to diseases. As the scientific community continues to investigate the functions and interactions of EVI2B, the development and refinement of EVI2B inhibitors are likely to play a crucial role in advancing our knowledge of this enigmatic protein and its implications for various biological contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Inhibits MEK1/2, downstream of Evi2B, in the MAPK pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Targets RAF kinases and inhibits downstream signaling. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
Blocks EGFR signaling, a pathway connected to Evi2B. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Targets VEGFR, EGFR, and RET, impacting Evi2B signaling. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Dual inhibitor of EGFR and HER2, part of Evi2B-related cascades. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Tyrosine kinase inhibitor, modulating Evi2B-associated pathways. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Targets multiple kinases, including those linked to Evi2B. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inhibits BCR-ABL and c-KIT kinases, affecting Evi2B pathways. | ||||||
Pazopanib Hydrochloride | 635702-64-6 | sc-364564 sc-364564A | 10 mg 25 mg | $107.00 $230.00 | 1 | |
Targets VEGFR, PDGFR, and c-Kit, impacting Evi2B signaling. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Inhibits BCR-ABL kinase, affecting Evi2B-related cascades. | ||||||